Uveitis Disease - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Uveitis Disease Emerging Therapy and TPP Insights

Thelansis's "Uveitis Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Uveitis Disease Overview

Uveitis is a heterogeneous group of intraocular inflammatory disorders affecting the uveal tract - iris, ciliary body, and choroid - classified anatomically as anterior, intermediate, posterior, or panuveitis, with anterior uveitis representing the most prevalent form. The pathophysiology encompasses both infectious triggers - including herpesviruses, toxoplasma, tuberculosis, and syphilis - and non-infectious immune-mediated mechanisms, the latter frequently associated with systemic conditions including HLA-B27-associated spondyloarthropathies, sarcoidosis, Behcet disease, juvenile idiopathic arthritis, and multiple sclerosis. Patients present with painful red eye, photophobia, blurred vision, and floaters - symptoms varying with anatomical location - while chronic or posterior uveitis may progress insidiously, threatening vision through cataract, glaucoma, cystoid macular oedema, and retinal detachment. Diagnosis integrates slit-lamp biomicroscopy, dilated fundoscopy, optical coherence tomography, fluorescein angiography, and targeted systemic workup to identify infectious or autoimmune aetiology. Corticosteroids - topical, periocular, or systemic - remain the therapeutic cornerstone for non-infectious disease, with steroid-sparing immunomodulators including methotrexate, mycophenolate, and azathioprine employed for chronic or recurrent disease. Biologics - particularly anti-TNF agents adalimumab, approved specifically for non-infectious uveitis - are utilised in refractory cases. Prognosis varies with aetiology, anatomical location, and treatment response; multidisciplinary collaboration, regular ophthalmological monitoring, and patient education are essential to preserving vision and quality of life.

Key Highlights

• In China, total prevalent uveitis cases are projected to increase from approximately 3,611,621 in 2025 to nearly 3,754,973 by 2035, reflecting a growing disease burden.
• Anterior uveitis remains the most common clinical subtype across diagnosed patient populations.
• Chronic and recurrent inflammation continues to contribute significantly to long-term visual impairment and reduced quality of life.
• Increasing use of immunosuppressive therapies and biologics is improving disease control in refractory non-infectious uveitis.
• Early diagnosis and multidisciplinary disease management remain critical to preventing irreversible ocular complications.

Market Overview

• The China uveitis market is projected to grow from approximately $80.70 MN in 2025 to nearly $97.30 MN by 2035, reflecting moderate market expansion.
• Market growth is supported by:
• Increasing adoption of biologics and steroid-sparing immunomodulatory therapies
• Improved diagnosis and long-term management of chronic and recurrent disease
• Market value growth is driven by rising treatment duration and increasing utilization of advanced ophthalmic therapies.
• Future market growth will depend on development of targeted immunotherapies, safer long-term treatment strategies, and improved management of refractory uveitis.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company